2010•Unpublished venueRequires access

Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor‐Positive Neuroendocrine Tumors

Martijn van Essen, Dik J. Kwekkeboom, Wouter W. de Herder, Lisa Bodei, Boen L.R. Kam, Marion de Jong, Roelf Valkema, Eric P. Krenning

Open publisher page 1 citations

Abstract

This chapter contains sections titled: Introduction Radiotherapy with 111In-Octreotide Radiotherapy with 90Y-DOTATOC Targeted Radiotherapy Studies with 177Lu-Octreotate PRRT with Other Somatostatin Analogues Comparison of Different PRRT Studies Comparison with Chemotherapy Options for Improving PRRT and Future Directions Conclusions References

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Radionuclide therapy, Peptide receptor, Somatostatin receptor, Octreotide, Somatostatin, Radiation therapy, Neuroendocrine tumors, Medicine